¥ê¥ó¥¯½¸
¥á¥¤¥ó | ÅÐÏ¿¤¹¤ë | ¿Íµ¤¥µ¥¤¥È (top10) | ¹âɾ²Á¥µ¥¤¥È (top10) | ¤ª¤¹¤¹¤á¥µ¥¤¥È (7) | Áê¸ß¥ê¥ó¥¯¥µ¥¤¥È (1) |
¥«¥Æ¥´¥ê°ìÍ÷ | RSS/ATOM Âбþ¥µ¥¤¥È (18) | RSS/ATOM µ»ö (66057) | ¥é¥ó¥À¥à¥¸¥ã¥ó¥× |
RSS/ATOM µ»ö (66057)
¤³¤³¤Ëɽ¼¨¤µ¤ì¤Æ¤¤¤ë RSS/ATOM µ»ö¤ò RSS ¤È ATOM ¤ÇÇÛ¿®¤·¤Æ¤¤¤Þ¤¹¡£
Æý¸Ï¢Æ°¡ý¥Ù¥ó¥Á¥ã¡¼¥¥ã¥Ô¥¿¥ëÄ´ºº2023¡¢UTEC¡¢À¤³¦É¸½à¤ÎVC¤òÌܻؤ·³¤³°Åê»ñ¤Ë¤âÃíÎÏ from Æü·Ð¥Ð¥¤¥ª¥Æ¥¯ONLINE (2023-5-23 7:00) |
¡¡ÅìµþÂç³Ø¥¨¥Ã¥¸¥¥ã¥Ô¥¿¥ë¥Ñ¡¼¥È¥Ê¡¼¥º¡ÊUTEC¡¢Åìµþ¡¦Ê¸µþ¡¢¶¿¼£Í§¹§¡Î¤´¤¦¤¸¡¦¤È¤â¤¿¤«¡Ï¼ÒĹ¡Ë¤Ï¡¢ÅìµþÂç¤Ë¼´Â¤òÃÖ¤¯¥Ù¥ó¥Á¥ã¡¼¥¥ã¥Ô¥¿¥ë¤È¤·¤Æ¡¢¤³¤ì¤Þ¤Ç¿¿ô¤Î¥¹¥¿¡¼¥È¥¢¥Ã¥×¤ËÅê»ñ¤ò¼Â»Ü¤·¤Æ¤¤¿¡£¹ñÆâ´ë¶È¤À¤±¤Ç¤Ê¤¯³¤³°´ë¶È¤Ø¤âÀѶËŪ¤ËÅê»ñ¤·¤Æ¤ª¤ê¡¢ÃÛ¤¤¤¿³¤³°¥Í¥Ã¥È¥ï¡¼¥¯¤Ç¹ñÆâ¤Î¥¹¥¿¡¼¥È¥¢¥Ã¥×¤Ë³¤³°¿Íºà¤ò¾Ò²ð¤¹¤ë¤Ê¤É¤Î¼è¤êÁȤߤâ¿Ê¤á¤Æ¤¤¤ë¡£UTEC¤Î¼èÄùÌò¤Ç¤¢¤ë±§º´ÈþÆƥѡ¼¥È¥Ê¡¼¤Ë¡¢¤½¤ÎÁÀ¤¤¤òʹ¤¤¤¿¡£
|
¥º¡¼¥à¥¢¥Ã¥×¡ý¥Ð¥¤¥ªÁ¡°Ý¡Ê¸åÊÔ¡Ë¡¢¥Ð¥¤¥ªÁ¡°Ý¡¢¥ß¥Î¥à¥·¤Ê¤É¤òÌÏÊ路¤¿¿·ÁǺà¤â³«È¯Ãæ¡¢¥¦¥¨¥¢¥é¥Ö¥ë¥Ç¥Ð from Æü·Ð¥Ð¥¤¥ª¥Æ¥¯ONLINE (2023-5-23 7:00) |
¡¡Á¡°Ý»º¶È¤ÏŤ¤Îò»Ë¤òͤ·¡¢¶áÂ建¶È¤ÎȯŸ¤Ë¤âÂ礤¯¹×¸¥¤·¤¿¤¬¡¢¥°¥í¡¼¥Ð¥ë²½¡¢¥Ç¥¸¥¿¥ë²½¡¢¥µ¥¹¥Æ¥Ê¥Ó¥ê¥Æ¥£¿ä¿Ê¤Îή¤ì¤Ê¤É¡¢Â¾¤Î»º¶È¤ÈƱÍͤˡ¢¼Ò²ñ¾õ¶·¤ÎÊѲ½¤Ë±þ¤¸¤¿Âбþ¤¬µá¤á¤é¤ì¤Æ¤¤¤ë¡£Æäˡ¢¥Þ¥¤¥¯¥í¥×¥é¥¹¥Á¥Ã¥¯ÌäÂê¤Ê¤É¡¢¥µ¥¹¥Æ¥Ê¥Ó¥ê¥Æ¥£¡¼Ì̤ǤβÝÂê¤Ï»³ÀѤ·¤Æ¤¤¤ë¡£¤½¤ÎÃæ¤Ç¡¢¥ê¥µ¥¤¥¯¥ë¤Î¿ä¿Ê¤äÁ¡°ÝÀ½ÉʤÎĹ¼÷Ì¿²½¤È¹ç¤ï¤»¤Æ¡¢¥Ð¥¤¥ªÁ¡°Ý¤¬ÃíÌܤò½¸¤á¤Æ¤¤¤ë¡£Á°ÊԤ˰ú¤Â³¤¡¢»Ô¾ì¤ä¸¦µæ³«È¯¤ÎÆ°¸þ¤ò¤Þ¤È¤á¤¿¡£
|
¥ê¥Ý¡¼¥ÈϢư¡ýÂæÏѥХ¤¥ª»º¶È¤ÎÆ°¸þ¡¢ÂæÏÑSteminent Biotherapeutics¼Ò¡¢ÂæÏѤǥ¹¥Æ¥à¥«¥¤¥Þ¥ë¤ÎÁá´ü¾µÇ§¤ from Æü·Ð¥Ð¥¤¥ª¥Æ¥¯ONLINE (2023-5-23 7:00) |
¡¡Steminent Biotherapeutics¼Ò¡ÊÃ粸À¸°å¡Ë¤Ï¡¢»éËÃͳÍè´´ºÙ˦¤Ë¤è¤ë¾²ÈºÙ˦ÎÅË¡¤Î³«È¯¤ò¿Ê¤á¤ëÂæÏÑ´ë¶È¤À¡£2016ǯ¤Ë¤ÏÀÔ¿ñ¾®Ç¾ÊÑÀ¾É¡ÊSCA¡Ë¤ËÂФ¹¤ë¾²È»éËÃͳÍè´´ºÙ˦¡ÖStemchymal¡Ê¥¹¥Æ¥à¥«¥¤¥Þ¥ë¡Ë¡×¤Ë¤Ä¤¤¤Æ¡¢¥ê¥×¥í¥»¥ë¤ËÆüËܤˤª¤±¤ë³«È¯¡¦ÈÎÇ丢¤òƳ½Ð¤·¤¿¡£¥¹¥Æ¥à¥«¥¤¥Þ¥ë¤Î³«È¯¾õ¶·¤äÂæÏѤλö¶È´Ä¶¤Ë¤Ä¤¤¤Æ¡¢Steminent¼Ò¤ÎLing-Mei Wang CEO¤ÈKevin Ho Director¤¬ËÜ»ï¤Î¼èºà¤Ë±þ¤¸¤¿¡£¡Ê¥¤¥ó¥¿¥Ó¥å¡¼²óÅú¤Ïξ¼Ô¡¢¸Ä¿Í̾ɽµÎ¬¡Ë¡£
|
¥¹¥Ú¥¤¥óARTHEx¼Ò¡¢¥Þ¥¤¥¯¥íRNAÄ´ÀáÌô¤ÎÎ×¾²³«È¯¤Ë¸þ¤±62²¯±ß¤òĴã from Æü·Ð¥Ð¥¤¥ª¥Æ¥¯ONLINE (2023-5-23 7:00) |
¡¡¥Þ¥¤¥¯¥íRNA¡ÊmiRNA¡ËÄ´ÀáÌô¤ò³«È¯¤·¤Æ¤¤¤ë¥¹¥Ú¥¤¥óARTHEx Biotech¼Ò¤Ï2023ǯ5·î3Æü¡¢¥·¥ê¡¼¥ºB¤Ç4200Ëü¥æ¡¼¥í¡ÊÌó62²¯±ß¡Ë¤òĴ㤷¤¿¤Èȯɽ¤·¤¿¡£ÆÀ¤é¤ì¤¿»ñ¶â¤Ï¡¢¶Ú¶¯Ä¾À¥¸¥¹¥È¥í¥Õ¥£¡¼1·¿¡ÊDM1¡Ë¤òÂоݤȤ·¤Æ³«È¯¤µ¤ì¤Æ¤¤¤ë¹³miR-23b¥¢¥ó¥Á¥»¥ó¥¹Ìô¤Ç¤¢¤ë¡¢ATX-01¤ÎÂè1/2aÁê»î¸³¤Î¿ä¿Ê¤ËÍѤ¤¤é¤ì¤ë¸«¹þ¤ß¤À¡£¤³¤Î»î¸³¤Î³«»Ï¤Ï2023ǯ²¼È¾´ü¤ËͽÄꤵ¤ì¤Æ¤¤¤ë¡£
|
Roche¼Ò¡¢¹á¹ÁZion Pharma¼Ò¤«¤éÆý¤¬¤óǾž°Ü¼£ÎŸþ¤±¤ËHER2-TKI¤òƳÆþ from Æü·Ð¥Ð¥¤¥ª¥Æ¥¯ONLINE (2023-5-23 7:00) |
¡¡¹á¹ÁZion Pharma¼Ò¤Ï2023ǯ5·î9Æü¡¢Æ±¼Ò¤Î¥ê¡¼¥É¥×¥í¥°¥é¥à¤Ç¤¢¤ëHER2¥Á¥í¥·¥ó¥¥Ê¡¼¥¼Á˳²ÌôZN-A-1041¤Ë¤Ä¤¤¤Æ¡¢À¤³¦Åª¤Ê³«È¯¤È¾¦Éʲ½¤Ë´Ø¤¹¤ë¸¢Íø¤ò¥¹¥¤¥¹Roche¼Ò¤Ë¶¡Í¿¤¹¤ë¤Èȯɽ¤·¤¿¡£ZN-A-1041¤Ï·ì±ÕǾ´ØÌç¤òÄ̲á¤Ç¤·Ð¸ýÅêÍ¿¤¬²Äǽ¤Ê²½¹çʪ¤Ç¡¢HER2ÍÛÀ¤Îž°ÜÀÆý¤¬¤ó´µ¼Ô¤ÎǾž°Ü¤Î¼£ÎŤª¤è¤ÓͽËɤòÌÜŪ¤Ë³«È¯¤µ¤ì¤Æ¤¤¤ë¡£
|
¥¯¥ê¥ó¥°¥ë¥Õ¥¡¡¼¥Þ¡¢HGFÀÔ¿ñ»½ýµÞÀ´ü¤Î¾µÇ§¿½ÀÁ¤Ï2024ǯ¤òÌÜɸ from Æü·Ð¥Ð¥¤¥ª¥Æ¥¯ONLINE (2023-5-23 7:00) |
¡¡¥¯¥ê¥ó¥°¥ë¥Õ¥¡¡¼¥Þ¤Ï2023ǯ5·î22Æü¡¢2023ǯ9·î´ü¤ÎÂè2»ÍȾ´ü¡Ê10·î¡Á3·î¡Ë·è»»ÀâÌÀ²ñ¤ò³«ºÅ¤·¤¿¡£Æ±¼Ò¤¬ÊÝͤ¹¤ë¡¢´ÎºÙ˦Áý¿£°ø»Ò¡ÊHGF¡Ë¤ÎÀÔ¿ñ»½ýµÞÀ´ü¤òÂоݤȤ·¤¿³«È¯¥Ñ¥¤¥×¥é¥¤¥ó¤Ë¤Ä¤¤¤Æ¡¢°Âã´î°ìÂåɽ¼èÄùÌò¼ÒĹ¤Ï¡Ö½çÄ´¤Ë¹Ô¤±¤Ð2024ǯ¤Ë¹ñÆâ¤Ç¾µÇ§¿½ÀÁ¤Ç¤¤ë¤È¹Í¤¨¤Æ¤¤¤ë¡×¤È¸«Ä̤·¤¿¡£
|
ÊÆSarepta¼Ò¤Î¶Ú¥¸¥¹°äÅÁ»Ò¼£ÎÅ¡¢FDA»ðÌä°Ñ°÷²ñ¤¬8ÂÐ6¤Î¶Ïº¹¤Ç¿×®¾µÇ§¤ò»Ù»ý from Æü·Ð¥Ð¥¤¥ª¥Æ¥¯ONLINE (2023-5-22 7:00) |
¡¡ÊÆSarepta Therapeutics¼Ò¤Ï2023ǯ5·î12Æü¡¢Æ±¼Ò¤Î¥Ç¥å¥·¥§¥ó¥Ì·¿¶Ú¥¸¥¹¥È¥í¥Õ¥£¡¼¤òÂоݤȤ¹¤ëSRP-9001°äÅÁ»Ò¼£ÎÅ¡Êdelandistrogene moxeparvovec¡Ë¤Î¿×®¾µÇ§¤ò¤á¤°¤Ã¤Æ¡¢ÊÆ¿©ÉÊ°åÌôÉʶɡÊFDA¡Ë¤ÎºÙ˦ÁÈ¿¥°äÅÁ»Ò¼£ÎÅ»ðÌä°Ñ°÷²ñ¤¬Åêɼ¤ò¹Ô¤¤¡¢8ÂÐ6¤Ç¿×®¾µÇ§¤ò»Ù»ý¤¹¤ë·ë²Ì¤Ë¤Ê¤Ã¤¿¤Èȯɽ¤·¤¿¡£¿³ºº¤Î½ªÎ»ÌÜɸÆü¤Ï2023ǯ5·î29Æü¤È¤Ê¤Ã¤Æ¤¤¤ë¡£
|
ÊÆInitial¼Ò¡¢É¸ÅªÃÁÇò¼Á¹çÀ®Ää»ßÌô¤Î¸¦µæ³«È¯¤Ë¥·¥ê¡¼¥ºA¤Ç102²¯±ß¤òĴã from Æü·Ð¥Ð¥¤¥ª¥Æ¥¯ONLINE (2023-5-22 7:00) |
¡¡Âç¼ê¥Ù¥ó¥Á¥ã¡¼¥¥ã¥Ô¥¿¥ë¤ÎÊÆApple Tree Partners¡ÊATP¡Ë¼Ò¤Ï2023ǯ5·î1Æü¡¢¿·ºîÍѵ¡½ø¤ÎÄãʬ»ÒÌô¤ò³«È¯¤¹¤ë¥Ý¡¼¥È¥Õ¥©¥ê¥ª´ë¶È¤ÎInitial Therapeutics¼Ò¤¬»ö¶È¤ò³«»Ï¤·¤¿¤Èȯɽ¤·¤¿¡£ATP¼Ò¤«¤é¥·¥ê¡¼¥ºA¤Ç7500Ëü¥É¥ë¡ÊÌó102²¯±ß¡Ë¤òĴ㤷¤¿Æ±¼Ò¤Ï¡¢Æȼ«¤ÎÁÏÌô¥×¥é¥Ã¥È¥Õ¥©¡¼¥à¤Ç¤¢¤ë¡ÖSTOPS¡§selective termination of protein synthesis¡×¤òÍѤ¤¡¢¤¬¤ó¤ò¤Ï¤¸¤á¤È¤¹¤ëÆñ¼£À¼À´µ¤òÂоݤˡ¢É¸ÅªÃÁÇò¼Á¤Î¹çÀ®¤òÄä»ß¤¹¤ë°åÌôÉʤθ¦µæ³«È¯¤òËܳʲ½¤¹¤ë¡£
|
Æý¸Ï¢Æ°¡ý¥Ù¥ó¥Á¥ã¡¼¥¥ã¥Ô¥¿¥ëÄ´ºº2023¡¢ÊÆAN Venture Partners¼Ò¡¢³¤³°Åê»ñ¤Î¸Æ¤Ó¹þ¤ßÁÀ¤¤Åê»ñÀè¤ÎËܼҤ from Æü·Ð¥Ð¥¤¥ª¥Æ¥¯ONLINE (2023-5-22 7:00) |
¡¡ÊÆAN Venture Partners¼Ò¤Ï¡¢ÆüËܤΥХ¤¥ª¥¹¥¿¡¼¥È¥¢¥Ã¥×¤ò¥°¥í¡¼¥Ð¥ë¤ËŸ³«¤µ¤»¤ë¤³¤È¤ò½Å»ë¤·¤Æ¤¤¤ë¡£2022ǯÁÏΩ¤Ç¡¢Âè1¹æ¥Õ¥¡¥ó¥É¤ò¶á¤¯ÁÈÀ®¤¹¤ë¡¢¿·¤·¤¤¥Ù¥ó¥Á¥ã¡¼¥¥ã¥Ô¥¿¥ë¡ÊVC¡Ë¤À¡£ÆÃħŪ¤Ê¤Î¤¬¡¢AN¥Ù¥ó¥Á¥ã¡¼¥º¼«¿È¤âÅê»ñÀ襹¥¿¡¼¥È¥¢¥Ã¥×¤â¡¢Êƹñ¤ËËܼҤòÃÖ¤¤¤Æ³èÆ°¤¹¤ëÅÀ¤À¡£2023ǯ4·î¡¢Æ±¼Ò¤Î¥Û¡¼¥óÀîÅè·òManaging Partner·óCEO¤¬ËÜ»ï¤Î¼èºà¤Ë±þ¤¸¡¢Åê»ñ¤ä¥Ï¥ó¥º¥ª¥ó»Ù±ç¤ÎÊý¿Ë¤ò¸ì¤Ã¤¿¡£
|
Elsevier¼Ò¤Î¿À·Ð·ÏÏÀʸ»ï¡¢Á´¥¨¥Ç¥£¥¿¡¼¤¬¼Ç¤¤·Æȼ«¤ËÈó±ÄÍøÏÀʸ»ï¤òÁÏ´© from Æü·Ð¥Ð¥¤¥ª¥Æ¥¯ONLINE (2023-5-22 7:00) |
¡¡2023ǯ4·î¡¢¥ª¥é¥ó¥ÀElsevier¼Ò¤ÎÏÀʸ»ï¡ÖNeuroImage¡×¤Ç¥¨¥Ç¥£¥¿¡¼¤ò̳¤á¤Æ¤¤¤¿40̾°Ê¾å¤Î¸¦µæ¼ÔÁ´°÷¤¬¡¢¥¨¥Ç¥£¥¿¡¼¤ò¼Ç¤¤·¤¿¡£¼Ç¤¤ÎÍýͳ¤ÏƱ»ï¤Ø¤Î·ÇºÜÎÁ¡ÊArticle Publishing Charge¡§APC¡Ë¤¬¹â³Û¤¹¤®¤ë¤³¤È¤À¤È¤¤¤¦¡£¸µ¥¨¥Ç¥£¥¿¡¼¤é¤ÏƱʬÌî¤Î¿·¤¿¤ÊÏÀʸ»ï¤òÁÏ´©¤¹¤ë¤³¤È¤òɽÌÀ¤·¤Æ¤¤¤ë¡£°ìÊý¤ÇElsevier¼Ò¦¤â¡¢¼ÒÆâ¤ÇNeuroImage»ï¤Î¿·¤¿¤ÊÊÔ½¸Éô¤òÁÈÀ®¤·¤¿¡£
|